Navigation Links
First Controlled Large-Scale Intervention Angiotensin Receptor,Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study,Demonstrates Significant Reduction in Blood Pressure and Protection,of Organs with Valsartan

rgans."

In the JIKEI HEART Study, treatment was initiated in a population with an average starting blood pressure of 139/81 mmHg -- already below the national guideline level for hypertension without comorbidities. The blood pressure target was set at 130/80 mmHg. The non-ARB group achieved 132/78 mmHg and the valsartan group achieved 131/77 mmHg. The valsartan group also showed a significant drop in composite cardiovascular events: the primary endpoint cardiovascular events were compared between the groups with the valsartan- added group exhibiting significant relative reductions, including a 65% reduction in angina pectoris, 46% in heart failure and 81% in aortic dissection. These benefits cannot be entirely explained by differences in blood pressure control.

"We are very proud that the University has led yet another landmark, large-scale clinical study. We are equally proud that the important findings of the JIKEI HEART Study were published in the prestigious general medical journal The Lancet, which also marks the 120-year anniversary of our first large-scale trial on beriberi published in the same medical journal," said Satoshi Kurihara, President, Jikei University School of Medicine. "In accordance with our mission of patient-centered medical care, the JIKEI HEART Study provides invaluable clinical insight into current and future treatments for the benefit of patients. We are grateful to the patients for their cooperation, and the physicians who ensured a high level of accuracy with a patient follow-up rate of 99%. The design of the physician-lead study provides a direction for future clinical investigations while attaining a high level of international commendation."

About the large-scale clinical JIKEI HEART Study

The JIKEI HEART Study was a multi-center comparative study with a prospective randomized open-label blinded endpoint (PROBE) design conducted by physicians. The study involved 3,081 Japanese patients aged 20 to 79 with h
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
(Date:7/30/2015)... PTC Therapeutics, Inc. (NASDAQ: PTCT ) ... for the second quarter ending June 30, 2015. ... the organization.  We are excited to be near the ... ever conducted with topline results expected in the fourth ... PTC Therapeutics, Inc. "Translarna is now commercially available in ...
(Date:7/30/2015)... , July 30, 2015  Cleveland Clinic President ... 2015 keynote address last month that industry is compelled ... order to gain the efficiencies—and develop the transformational innovations ... Dr. Barsoum,s comments were preceded by Doug Kohrs ... and OMTEC moderator, who stressed that industry must add ...
(Date:7/30/2015)... , July 30, 2015 ... latest report titled, "Continuous Glucose Monitoring Systems Market: Global ... to the report, the global continuous glucose monitoring systems ... and is expected to reach US$ 788.4 Mn by ... period, 2015 to 2020. Global continuous glucose ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4
(Date:7/31/2015)... ... July 31, 2015 , ... The Mount Sinai Health System will work with ... potential of related, experimental treatments. The collaboration moves into the next phase with the ... one of five state licenses to produce and dispense medical marijuana. , Mount ...
(Date:7/31/2015)... ... July 31, 2015 , ... Recently, ZKB ... of Ohio, Western Division (Case No. 3:15-cv-00397) involving the Implanon® contraceptive implant ... spontaneous migration of their Implanon® implants, inability to locate the implants, unsuccessful and ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida ... novel catheter that was developed for targeted delivery of fluids to selected sites ... treated at Florida Hospital Tampa with the device that provides direct, local delivery ...
(Date:7/31/2015)... ... July 31, 2015 , ... Awarded to only the Top 10 hair ... that they are the latest recipients of the Center of Clinical Excellence for ... the worldwide leaders in the science of hair transplant. , Parsa Mohebi Hair Restoration ...
(Date:7/31/2015)... ... July 31, 2015 , ... Healthpointe ... a newly redesigned website at Healthpointe.net. The new website will feature a sleek ... The redesign serves to provide smoother interactions between patients and the Healthpointe clinics ...
Breaking Medicine News(10 mins):Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Prestigious Medical Award Given To Parsa Mohebi Hair Restoration for Excellence in Hair Transplantation 2Health News:Healthpointe Announces Newly Redesigned Website 2
... ... been developed. Experienced weight loss physicians have raised the HCG diet caloric daily allowance from ... diet protocol written 50 years ago. The physician’s goal with this new HCG diet protocol ... patients. , ...
... ... place on May 6, 2010. Two years in the planning and development, the cutting-edge ... nonsurgical laser treatments for varicose veins and spider veins. , ... Prescott, AZ (PRWEB) April 27, 2010 -- Prescott Vein Specialties ...
... with chronic kidney disease have more severe anemia than white ... a multicenter study led by Johns Hopkins Children,s Center to ... Journal of Kidney Disease . The findings suggest that ... may be at play, raising the question whether current guidelines ...
... studies finds that patients, research participants and journal readers ... disclosed, in part because those financial ties may influence ... the April 26 issue of Archives of Internal ... ties to the pharmaceutical, biotechnology and medical device industries ...
... ─ Tiny, melanin-covered nanoparticles may protect bone marrow from ... at Albert Einstein College of Medicine of Yeshiva University ... these particles into human patients may hold promise in ... issue of the International Journal of Radiation Oncology, ...
... are most likely to be good candidates upon death, ... U.S. researchers have developed a new tool that may ... donors, a development that could potentially boost organ donation ... often good candidates for organ donation when they die ...
Cached Medicine News:Health News:Breakthrough in HCG Weight Loss Therapy 2Health News:Breakthrough in HCG Weight Loss Therapy 3Health News:New Varicose Vein Treatment Center Opens in Prescott, Arizona 2Health News:Anemia tougher to tackle in black children with kidney disease 2Health News:Patients, clinicians favor disclosure of financial ties to industry 2Health News:Patients, clinicians favor disclosure of financial ties to industry 3Health News:Novel nanoparticles prevent radiation damage 2Health News:Novel nanoparticles prevent radiation damage 3Health News:Novel nanoparticles prevent radiation damage 4Health News:Test Spots Potential Organ Donors Among Coma Patients 2
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... With membrane parasite ... and cytoplasm as antigen. ... different antigens than the ... possible to use two ...
Elisa test for qualitative detection of Total antibodies to Trypanosoma Cruzi in human serum or plasma....
Silicone ICD lead...
Medicine Products: